TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37178149

Group type: EXPERIMENTAL
Intervention: Right median nerve electrical stimulation (RMNS) - 20 mA, 300 μs, 40 Hz stimulation pulses, lasting 20 s per minute, 8 h per day, for 2 weeks.
Number of subjects: 329

Group type: COMPARATOR
Intervention: Routine treatment (control group)
Number of subjects: 329

Group type: EXPERIMENTAL
Intervention: RMNS group
Number of subjects: 329
Study: 37178160

Group type: EXPERIMENTAL
Intervention: Ultra-fast fluorescence confocal microscopy imaging
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Training program composed of 110 images divided into nine learning sessions
Number of subjects: 181
Study: 37178435

Group type: EXPERIMENTAL
Intervention: Oral Semaglutide
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Subcutaneous Semaglutide
Number of subjects: 4
Study: 37178442

Group type: EXPERIMENTAL
Intervention: Presence of small ONH
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Presence of ONH tilt
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Presence of LC defects
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Presence of LC defects and thicker LC
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Axial length > 28 mm
Number of subjects: 200
Study: 37178517

Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRS) for neuroticism
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral and cognitive variables (fear, interoceptive, reward, cognitive variables)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Machine learning ensemble method
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Emotional and interoceptive processing targeting
Number of subjects: 0
Study: 37178647

Group type: EXPERIMENTAL
Intervention: Afatinib 18 mg/m²/d
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Afatinib 23 mg/m²/d
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Afatinib
Number of subjects: 56
Study: 37178702

Group type: EXPERIMENTAL
Intervention: Molecular testing-guided therapy (first-line treatment)
Number of subjects: 880

Group type: COMPARATOR
Intervention: Susceptibility testing-guided therapy (first-line treatment)
Number of subjects: 880

Group type: EXPERIMENTAL
Intervention: Molecular testing-guided therapy (third-line treatment)
Number of subjects: 880

Group type: COMPARATOR
Intervention: Susceptibility testing-guided therapy (third-line treatment)
Number of subjects: 880
Study: 37178706

Group type: EXPERIMENTAL
Intervention: nOPV2 only
Number of subjects: 736

Group type: EXPERIMENTAL
Intervention: nOPV2 plus bOPV
Number of subjects: 736

Group type: COMPARATOR
Intervention: bOPV only
Number of subjects: 736
Study: 37178932

Group type: EXPERIMENTAL
Intervention: Semi-weekly (BIW) focal boosted prostate SBRT delivering 35 Gy in 5 fractions with an iso-toxic boost up to 50 Gy
Number of subjects: 124

Group type: COMPARATOR
Intervention: Once-weekly (QW) focal boosted prostate SBRT
Number of subjects: 124
Study: 37178978

Group type: EXPERIMENTAL
Intervention: Saturated fatty acid (SFA) density
Number of subjects: 81894

Group type: EXPERIMENTAL
Intervention: Polyunsaturated fatty acid (PUFA) density
Number of subjects: 81894

Group type: EXPERIMENTAL
Intervention: Higher SFA and PUFA diets
Number of subjects: 81894
Study: 37179240

Group type: EXPERIMENTAL
Intervention: Enzalutamide plus ADT
Number of subjects: 927

Group type: COMPARATOR
Intervention: Placebo plus ADT
Number of subjects: 927
Study: 37179297

Group type: EXPERIMENTAL
Intervention: SRP plus omega-3 PUFAs (EPA and DHA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: SRP alone (Control)
Number of subjects: 40
Study: 37179349

Group type: EXPERIMENTAL
Intervention: Pyronaridine-artesunate (PA)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Artemether-lumefantrine (AL)
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Both PA and AL
Number of subjects: 172
Study: 37179415

Group type: EXPERIMENTAL
Intervention: 12-week home-based physical activity intervention aiming to increase daily steps by 2000 from baseline
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 12-week home-based physical activity intervention
Number of subjects: 120
Study: 37179438

Group type: EXPERIMENTAL
Intervention: Patients sleeping ≥9 h
Number of subjects: 1175

Group type: EXPERIMENTAL
Intervention: Patients sleeping ≤5 h
Number of subjects: 1175
Study: 37179458

Group type: EXPERIMENTAL
Intervention: Caregiver-delivered cognitive stimulation therapy (CDCST) for 15 weeks
Number of subjects: 241

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 241

Group type: EXPERIMENTAL
Intervention: Caregiver-delivered cognitive stimulation therapy (CDCST)
Number of subjects: 241
Study: 37179526

Group type: EXPERIMENTAL
Intervention: Single-fraction stereotactic ablative body radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Multifraction stereotactic ablative body radiotherapy
Number of subjects: 0
Study: 37179530

Group type: EXPERIMENTAL
Intervention: Multimodal mechanical stimulation therapy (M-Stim) with three vibration motors (50 Hz, 100 Hz, 200 Hz) and amplitudes between 0.1-0.3 m/s for 20 minutes.
Number of subjects: 20
Study: 37179555

Group type: EXPERIMENTAL
Intervention: Epidural spinal cord stimulation (ESCS)
Number of subjects: 3
Study: 37179566

Group type: EXPERIMENTAL
Intervention: Active cerebellar tACS
Number of subjects: 164

Group type: COMPARATOR
Intervention: Sham cerebellar tACS
Number of subjects: 164
Study: 37179746

Group type: EXPERIMENTAL
Intervention: SAT-008 digital device
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 32
Study: 37179936

Group type: EXPERIMENTAL
Intervention: Machine learning predicted structural progression based on baseline s-scores
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Kellgren-Lawrence (KL) grades
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Radiographic measurements (JSW, subchondral bone density, osteophytes)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: MRI quantitative measurements (cartilage thickness)
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Radiographic osteophyte size
Number of subjects: 237

Group type: EXPERIMENTAL
Intervention: Overall structural progression
Number of subjects: 237
Study: 37180085

Group type: EXPERIMENTAL
Intervention: Carotenoid intake screener
Number of subjects: 0
Study: 37180209

Group type: EXPERIMENTAL
Intervention: Gilteritinib (XOSPATA®)
Number of subjects: 17
Study: 37180228

Group type: EXPERIMENTAL
Intervention: Lactulose (synbiotic) for 12 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: COMPARATOR
Intervention: NIP group (no intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Synbiotic
Number of subjects: 0
Study: 37180415

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) assessment using the Pediatric Quality of Life Inventory (PedsQL)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Health-related quality of life (HRQoL) assessment
Number of subjects: 36
Study: 37180427

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37180469

Group type: EXPERIMENTAL
Intervention: Nomogram based on multivariate logistic regression
Number of subjects: 2631

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 2631

Group type: EXPERIMENTAL
Intervention: Glasgow Coma Scale score
Number of subjects: 2631

Group type: EXPERIMENTAL
Intervention: Injury Severity Score
Number of subjects: 2631

Group type: EXPERIMENTAL
Intervention: Abnormal pupil status
Number of subjects: 2631

Group type: EXPERIMENTAL
Intervention: Midline shift
Number of subjects: 2631

Group type: EXPERIMENTAL
Intervention: Pre-hospital intubation
Number of subjects: 2631
Study: 37180485

Group type: EXPERIMENTAL
Intervention: Macadamia nuts (~15% of daily calories) for 8 weeks
Number of subjects: 35

Group type: COMPARATOR
Intervention: Usual diet without nuts for 8 weeks (Control)
Number of subjects: 35
Study: 37180499

Group type: EXPERIMENTAL
Intervention: Height-adjusted total kidney volume (htTKV) on MRI
Number of subjects: 84
Study: 37180505

Group type: EXPERIMENTAL
Intervention: Iptacopan 200 mg twice daily for 24 months
Number of subjects: 450

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 450
Study: 37180506

Group type: EXPERIMENTAL
Intervention: Sparsentan
Number of subjects: 404

Group type: COMPARATOR
Intervention: Irbesartan (active control)
Number of subjects: 404
Study: 37180745

Group type: EXPERIMENTAL
Intervention: Behavioral intersectional stigma coping intervention (three weekly 2-h group sessions)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Usual services only (control)
Number of subjects: 100
Study: 37180808

Group type: EXPERIMENTAL
Intervention: Reverse T and Protrusion (rTAP)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Double-kissing and crush (DKC)
Number of subjects: 52
Study: 37180814

Group type: EXPERIMENTAL
Intervention: Acrysof® IQ Vivity® IOL
Number of subjects: 30
Study: 37180843

Group type: EXPERIMENTAL
Intervention: Rivaroxaban 2.5 mg twice daily
Number of subjects: 276

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study: 37181036

Group type: EXPERIMENTAL
Intervention: Short-term rapid severe hypothyroidism induced by thyroid hormone withdrawal
Number of subjects: 75

Group type: COMPARATOR
Intervention: Euthyroid state before thyroidectomy
Number of subjects: 75
Study: 37181123

Group type: EXPERIMENTAL
Intervention: Counseling on healthy eating practices for 1 year postpartum
Number of subjects: 0

Group type: COMPARATOR
Intervention: No counseling (Control)
Number of subjects: 0
Study: 37181130

Group type: EXPERIMENTAL
Intervention: Puerto Rican Optimized Mediterranean-like Diet (PROMED) intervention group received 1 individual nutritional counseling session on a portion-control culturally-tailored MedDiet, daily text messages for 2 months, and supplied legumes and vegetable oils.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group received cooking utensils and one standard portion-control nutritional counseling session reinforced with daily texts for 2 months.
Number of subjects: 50
Study: 37181156

Group type: EXPERIMENTAL
Intervention: High fiber (∼38 g/d) plant-based diet
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Addition of inulin-type fructans (ITF) to the plant-based diet
Number of subjects: 100
Study: 37181388

Group type: EXPERIMENTAL
Intervention: Clopidogrel monotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Aspirin monotherapy
Number of subjects: 0
Study: 37181420

Group type: EXPERIMENTAL
Intervention: Pimecrolimus 1% cream as maintenance therapy after baseline therapy with topical glucocorticoids (group 1)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Topical glucocorticoids without subsequent use of pimecrolimus (group 2)
Number of subjects: 108
Study: 37181803

Group type: EXPERIMENTAL
Intervention: Fit-metabolic syndrome (14.4%)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Unfit-metabolic syndrome (36.2%)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Fit-dysmetabolism (not specified percentage)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Unfit-dysmetabolism (not specified percentage)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Fit-metabolically healthy (19.5%)
Number of subjects: 492

Group type: EXPERIMENTAL
Intervention: Unfit-metabolically healthy (29.9%)
Number of subjects: 492
Study: 37181877

Group type: EXPERIMENTAL
Intervention: Mock Interview Rating Scale (MIRS)
Number of subjects: 90
Study: 37181888

Group type: EXPERIMENTAL
Intervention: Single dose of oral psilocybin (0.25 mg/kg)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Active placebo-control agent (250 mg of niacin)
Number of subjects: 30
Study: 37181927

Group type: EXPERIMENTAL
Intervention: Highest quartile of chronotype polygenic score
Number of subjects: 0

Group type: COMPARATOR
Intervention: ChooseWell 365 intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chronotype polygenic score
Number of subjects: 0

Group type: COMPARATOR
Intervention: Workplace healthy eating intervention
Number of subjects: 0
Study: 37181931

Group type: EXPERIMENTAL
Intervention: Global Diet Quality Score (GDQS) in the second tercile
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increased protein intake
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nutritional status and socioeconomic factors
Number of subjects: 0
Study: 37181933

Group type: EXPERIMENTAL
Intervention: Mothers-only arm
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Parents-combined arm
Number of subjects: 390

Group type: EXPERIMENTAL
Intervention: Higher maternal social support
Number of subjects: 390
Study: 37181935

Group type: EXPERIMENTAL
Intervention: Food service staff training focused on Child and Adult Care Food Program (CACFP) best practices
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Best-practice menu with healthy recipes
Number of subjects: 9
Study: 37181934

Group type: EXPERIMENTAL
Intervention: Quadruple-fortified salt (QFS; iron, iodine, folic acid, vitamin B)
Number of subjects: 0
Study: 37181936

Group type: EXPERIMENTAL
Intervention: 1 egg/d for 6 months
Number of subjects: 489
Study: 37182298

Group type: EXPERIMENTAL
Intervention: Alert-based computerized decision support (CDS)
Number of subjects: 798

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 798
Study: 37182434

Group type: COMPARATOR
Intervention: MA (160 mg orally daily)
Number of subjects: 180

Group type: COMPARATOR
Intervention: LNG-IUS
Number of subjects: 180

Group type: COMPARATOR
Intervention: MA + LNG-IUS (MA 160 mg orally daily plus LNG-IUS)
Number of subjects: 180

Group type: COMPARATOR
Intervention: MA
Number of subjects: 180
Study: 37182529

Group type: EXPERIMENTAL
Intervention: Mailed HPV self-collection kit with scheduling assistance
Number of subjects: 665

Group type: COMPARATOR
Intervention: Scheduling assistance alone (control)
Number of subjects: 665
Study: 37182534

Group type: EXPERIMENTAL
Intervention: Sulbactam-durlobactam (1·0 g of each drug in combination over 3 h every 6 h for 7-14 days)
Number of subjects: 181

Group type: COMPARATOR
Intervention: Colistin (2·5 mg/kg over 30 min every 12 h for 7-14 days)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Sulbactam-durlobactam
Number of subjects: 181

Group type: COMPARATOR
Intervention: Colistin
Number of subjects: 181
Study: 37182538

Group type: EXPERIMENTAL
Intervention: Dalpiciclib plus letrozole or anastrozole
Number of subjects: 456

Group type: COMPARATOR
Intervention: Placebo plus letrozole or anastrozole
Number of subjects: 456
Study: 37182692

Group type: EXPERIMENTAL
Intervention: Hypocaloric Ketogenic Diets (KDs)
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: Higher levels of ketosis
Number of subjects: 199

Group type: EXPERIMENTAL
Intervention: ß-Hydroxybutyrate (ßHB) plasma concentrations
Number of subjects: 199
Study: 37182695

Group type: EXPERIMENTAL
Intervention: Maternal UIC ≥250 μg/L
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Maternal TSI >90th quantiles
Number of subjects: 469

Group type: EXPERIMENTAL
Intervention: Maternal TSH ≥2.5 mIU/L
Number of subjects: 469
Study: 37182704

Group type: EXPERIMENTAL
Intervention: 6-minute walking test (6WT)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Visual analogue scale (VAS)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Core outcome measure index (COMI)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Zurich claudication questionnaire (ZCQ)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Ceiling effect assessment
Number of subjects: 50
Study: 37182818

Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 20
Study: 37183098

Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride 1% i.v. at a dose of 1.5 mg/kg
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study: 37183103

Group type: EXPERIMENTAL
Intervention: Group B (≤2 years since chemotherapy completion)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy
Number of subjects: 36

Group type: COMPARATOR
Intervention: Overall cognition and memory
Number of subjects: 36
Study: 37183104

Group type: EXPERIMENTAL
Intervention: EFICANCER individualized and supervised exercise program
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (standard oncological care)
Number of subjects: 90
Study: 37183115

Group type: EXPERIMENTAL
Intervention: Bendamustine/Rituximab (BR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cytarabine/Rituximab (CR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bendamustine/Rituximab (BR) with Acalabrutinib
Number of subjects: 0
Study: 37183368

Group type: EXPERIMENTAL
Intervention: Project Personality (PP; N=482)
Number of subjects: 996

Group type: EXPERIMENTAL
Intervention: Action Brings Change Project (ABC; N=514)
Number of subjects: 996
Study: 37183454

Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy for 24 weeks
Number of subjects: 770

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 770

Group type: EXPERIMENTAL
Intervention: Relugolix combination therapy (delayed: relugolix alone for 12 weeks, then combination for 12 weeks)
Number of subjects: 770
Study: 37183520

Group type: EXPERIMENTAL
Intervention: Setanaxib 400 mg OD
Number of subjects: 111

Group type: EXPERIMENTAL
Intervention: Setanaxib 400 mg BID
Number of subjects: 111

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 111
Study: 37183528

Group type: EXPERIMENTAL
Intervention: Pembrolizumab 200 mg plus chemotherapy (paclitaxel 200 mg/m2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy (paclitaxel 200 mg/m2)
Number of subjects: 0
Study: 37183700

Group type: EXPERIMENTAL
Intervention: AVO algorithm (SmartDelay)
Number of subjects: 310

Group type: COMPARATOR
Intervention: Fixed atrioventricular delay of 120 ms with biventricular pacing
Number of subjects: 310
Study: 37183779

Group type: EXPERIMENTAL
Intervention: Brepocitinib 60 mg single oral dose
Number of subjects: 6
Study: 37183819

Group type: EXPERIMENTAL
Intervention: SBRT+P (Stereotactic Body Radiotherapy plus Pembrolizumab)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: SBRT+P
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: High-RS (CD8+ T cell radiomics score)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Elevated circulating IL-8
Number of subjects: 97
Study: 37183837

Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF (100 μg/kg body weight, maximum total dosage of 6 mg) administered once 24-48 hours following chemotherapy for two cycles
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: PEG-rhG-CSF
Number of subjects: 160
Study: 37183871

Group type: EXPERIMENTAL
Intervention: 3-hydroxybutyrate (3-OHB) infusion
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 20
Study: 37183883

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Number of subjects: 3364

Group type: EXPERIMENTAL
Intervention: Ornithine phenylacetate
Number of subjects: 3364

Group type: EXPERIMENTAL
Intervention: 13 C-methacetin breath test (MBT)
Number of subjects: 3364

Group type: EXPERIMENTAL
Intervention: Rotational thromboelastometry
Number of subjects: 3364
Study: 37184071

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 37184136

Group type: EXPERIMENTAL
Intervention: Izokibep, a novel IL-17A neutralizing Affibody molecule, dosage and duration not specified
Number of subjects: 0
Study: 37184216

Group type: EXPERIMENTAL
Intervention: Low-energy amplitude-modulated electromagnetic field exposure (AutEMdev)
Number of subjects: 66
Study: 37184292

Group type: EXPERIMENTAL
Intervention: Combined hormonal contraception
Number of subjects: 314704

Group type: COMPARATOR
Intervention: Non-users of hormonal contraception
Number of subjects: 314704
Study: 37184470

Group type: EXPERIMENTAL
Intervention: Different exercise modalities and intensities
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 37184523

Group type: EXPERIMENTAL
Intervention: Maralixibat ≤10 mg/d for 14 weeks
Number of subjects: 27
Study: 37184602

Group type: EXPERIMENTAL
Intervention: 1-Week CGM Home Test, Nocturnal Glucose Increments, and Standardized Liquid Mixed Meal Breakfasts
Number of subjects: 0
Study: 37184615

Group type: EXPERIMENTAL
Intervention: Training for criminal legal staff to address public stigma
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Group-based acceptance and commitment therapy to address self-stigma
Number of subjects: 0
Study: 37184828

Group type: EXPERIMENTAL
Intervention: Crisaborole QD
Number of subjects: 270

Group type: COMPARATOR
Intervention: Vehicle QD
Number of subjects: 270
Study: 37184839

Group type: EXPERIMENTAL
Intervention: Esmolol 14% gel with standard of care (SoC)
Number of subjects: 176

Group type: EXPERIMENTAL
Intervention: Esmolol 14% gel with SoC
Number of subjects: 176

Group type: COMPARATOR
Intervention: SoC only
Number of subjects: 176
Study: 37184872

Group type: EXPERIMENTAL
Intervention: Standard care plus low-level stochastic vibrotactile stimulation (SVS) using a vibrating crib mattress with a 3-hour on-off cycle.
Number of subjects: 208

Group type: COMPARATOR
Intervention: Treatment as usual (TAU).
Number of subjects: 208

Group type: EXPERIMENTAL
Intervention: SVS (vibrating mattress).
Number of subjects: 208
Study: 37184896

Group type: EXPERIMENTAL
Intervention: ACT-based mHealth intervention
Number of subjects: 34
Study: 37184905

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Guided Relaxation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 37185188

Group type: EXPERIMENTAL
Intervention: Supervised pelvic floor muscle training (PFMT) with a home-based pressure-mediated biofeedback device
Number of subjects: 500

Group type: COMPARATOR
Intervention: At-home pelvic floor muscle training (PFMT) alone
Number of subjects: 500
Study: 37185191

Group type: EXPERIMENTAL
Intervention: Digital technologies for motor rehabilitation
Number of subjects: 500
Study: 37185193

Group type: EXPERIMENTAL
Intervention: Discontinuation of levothyroxine treatment after a control period of 12 weeks, with gradual discontinuation and regular monitoring of thyroid function.
Number of subjects: 513

Group type: COMPARATOR
Intervention: Control period of 12 weeks with continuous levothyroxine treatment.
Number of subjects: 513
Study: 37185197

Group type: EXPERIMENTAL
Intervention: Continuous intravenous remimazolam
Number of subjects: 150

Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 150
Study: 37185231

Group type: EXPERIMENTAL
Intervention: Actigraphy-based sleep duration and continuity measures (24-hour and nocturnal sleep duration, sleep fragmentation index, sleep efficiency)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Actigraphy-based sleep duration and continuity measures
Number of subjects: 298
Study: 37185272

Group type: EXPERIMENTAL
Intervention: EP-FGR infants
Number of subjects: 135
Study: 37185596

Group type: EXPERIMENTAL
Intervention: 12 mg OTO-104
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174